CD4 and influenza: mRNA-1010 demonstrated durable humoral responses, higher influenza A HAI GMTs and broader antibody responses than a licensed quadrivalent influenza vaccine (Afluria), and robust cellular CD4+ T-cell responses as compared with placebo.